CLK/CDK inhibitor (SRI International)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameCLK/CDK inhibitor (SRI International)
Drug Alias NameSecond generation CLK/CDK inhibitor (SRI International)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase inhibitorsClk dual-specificity kinase inhibitors
TargetsDual specificity protein kinase CLKCyclin-dependent kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSri International
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSri International
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A